Lu AG08854 (L1CAM mAb)
Alzheimer's Disease
PreclinicalResearch stage
Key Facts
About Lundbeck
Lundbeck is a specialized biopharmaceutical company dedicated entirely to brain diseases, distinguishing itself as one of the few companies worldwide with this exclusive focus. The company leverages over seven decades of neuroscience expertise to develop and commercialize therapies for psychiatric and neurological disorders, including depression, schizophrenia, Alzheimer's disease, and migraine. As a 'Focused Innovator,' Lundbeck is building on its legacy to serve neuro-rare communities through bold science and deep patient commitment. The company operates globally, with approximately 1,000+ colleagues in the U.S. alone, working to deliver innovative treatments and support patient communities.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Donanemab | Eli Lilly | Phase 3 |
| ALN-APP | Alnylam Pharmaceuticals | Phase 1 |
| Alzheimer's Disease Program | Roche | Various |
| UCB0022 | UCB | Phase 1 |
| Lecanemab (Leqembi) | Eisai | Commercial |
| ARO-MAPT | Arrowhead Pharmaceuticals | Pre-clinical |
| AMBAR® | Grifols | Clinical |
| DNL919 | Denali Therapeutics | Phase 1b |
| BAN2802 | BioArctic AB | Preclinical |
| Lecanemab SC | BioArctic AB | Phase 3 |
| Undisclosed Program | uniQure | Preclinical |
| NVG-291 | NervGen Pharma | Phase 1b/2a |